We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+13.24%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.44B
AUM Growth
-$133M
Cap. Flow
-$77.2M
Cap. Flow %
-3.16%
Top 10 Hldgs %
50.14%
Holding
73
New
3
Increased
9
Reduced
33
Closed
4

Top Buys

1
AKRO
Akero Therapeutics
AKRO
+$44.6M
2
PRME icon
Prime Medicine
PRME
+$39.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$34.8M
4
REPL icon
Replimune Group
REPL
+$24.7M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.5M

Top Sells

1
ARGX icon
argenx
ARGX
+$49.2M
2
PRTA icon
Prothena Corp
PRTA
+$31.9M
3
ONEM
1Life Healthcare
ONEM
+$29.7M
4
SKIN icon
SkinHealth Systems
SKIN
+$24.9M
5
LIVN icon
LivaNova
LIVN
+$22M

Sector Composition

1 Healthcare 98.91%
2 Industrials 0.92%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$1.81B
$5.93M 0.24%
642,430
-193,400
-23% -$2.01M
NUVB icon
52
Nuvation Bio
NUVB
$2.02B
$5.82M 0.24%
3,031,009
– –
CABA icon
53
Cabaletta Bio
CABA
$465M
$4.29M 0.18%
464,252
-232,125
-33% -$845K
NVTA
54
DELISTED
Invitae Corporation
NVTA
$4.24M 0.17%
2,280,403
– –
SLGC
55
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.77M 0.15%
1,500,000
-370,839
-20% -$1.03M
TKNO icon
56
Alpha Teknova
TKNO
$292M
$3.15M 0.13%
558,099
– –
STXS icon
57
Stereotaxis
STXS
$153M
$3.08M 0.13%
1,487,495
– –
GRFS
58
Grifois
GRFS
$4.93B
$2.77M 0.11%
+325,600
New +$2.37M
TOI icon
59
The Oncology Institute
TOI
$536M
$2.61M 0.11%
1,583,158
– –
HOOK
60
DELISTED
HOOKIPA Pharma
HOOK
$2.52M 0.1%
311,477
-144,748
-32% -$1.57M
IVVD icon
61
Invivyd
IVVD
$219M
$2.16M 0.09%
1,440,725
-480,235
-25% -$1.34M
ACHL
62
DELISTED
Achilles Therapeutics
ACHL
$1.45M 0.06%
1,608,089
– –
SONX
63
DELISTED
Sonendo, Inc.
SONX
$1.41M 0.06%
498,131
– –
BVS icon
64
Bioventus
BVS
$817M
$1.4M 0.06%
535,950
-763,189
-59% -$3.33M
XERS icon
65
Xeris Biopharma Holdings
XERS
$1.52B
$1.39M 0.06%
1,046,587
– –
NGNE icon
66
Neurogene
NGNE
$747M
$942K 0.04%
92,528
-79,319
-46% -$819K
TCRR
67
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$731K 0.03%
731,379
-363,266
-33% -$490K
CTSO icon
68
Cytosorbents Corp
CTSO
$22.9M
$413K 0.02%
266,365
– –
BCEL
69
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$354K 0.01%
442,653
-357,653
-45% -$455K
HUM icon
70
Humana
HUM
$48B
– –
-16,961
Closed -$8.23M
PRTA icon
71
Prothena Corp
PRTA
$453M
– –
-525,575
Closed -$31.9M
SKIN icon
72
SkinHealth Systems
SKIN
$109M
– –
-2,109,564
Closed -$24.9M
CUTR
73
DELISTED
Cutera, Inc.
CUTR
– –
-194,573
Closed -$8.87M
1 2
3

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q4 2022 Portfolio in Review

As of Q4 2022, Redmile Group held 73 positions worth $2.44B, down 5.2% from $2.58B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group withdrew a net $77.2M in Q4 2022, closing 4 positions and reducing 33 holdings. Its most notable exit was Prothena Corp, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Prime Medicine worth $41M.

  • Redmile Group's largest Q4 2022 buy was Prime Medicine: 2,209,350 shares worth $41M.
  • Redmile Group added most to Akero Therapeutics in Q4 2022, an estimated $44.6M increase.
  • Redmile Group's biggest Q4 2022 reduction was argenx, cutting an estimated $49.2M.
  • Redmile Group fully exited Prothena Corp in Q4 2022, selling an estimated $31.9M.
  • Redmile Group's ten largest holdings make up 50% of its $2.44B portfolio in Q4 2022.
  • Redmile Group opened 3 new positions and closed 4 in Q4 2022.
  • Redmile Group's portfolio value fell 5.2% quarter-over-quarter to $2.44B.

Based on Redmile Group's 13F filing for Q4 2022, filed 14 Feb 2023.